National Law Firm Investigates Cases of Permanent Hair Loss due to Cancer Drug
The chemotherapy drug Taxotere has been linked to permanent alopecia in female patients. Drug maker is accused of failure to warn patients and doctors.
By: Arentz Law Group
“Loss of hair occurs in most patients taking Taxotere (including the hair on your head, underarm hair, pubic hair, eyebrows, and eyelashes). Hair loss will begin after the first few treatments and varies from patient to patient. Once you have completed all your treatments, hair generally grows back.”
Last year, due to numerous reports of persistant hair loss, the FDA finally responded to patient concerns by issuing a label change listing permanent alopecia. The new label became effective on November 24, 2015.
It has been estimated that up to 75% of breast cancer patients who have undergone chemotherapy have been prescribed Taxotere. Furthermore, research published by the National Cancer Research Institute found that 10-15% of patients prescribed the medication suffered permanent hair loss.
The attorneys of Arentz Law Group believe that women facing breast cancer treatment deserve all the facts about their treatment and that drug companies must be held accountable when it comes to providing known side effect information. Female alopecia due to chemotherapy has been linked to mental distress and can have serious effects on quality of life for many women. Those not properly warned of the potential for permanent hair loss after treatment with Taxotere may be entitled to compensation from the drug company. Free legal consultations are available for women who have suffered permanent hair loss due to Taxotere by calling 1-800-305-6000 or by completing the claim qualification form at ArentzLaw.com.